Purdue University-based LyoHUB charts a risk-based course to modernizing freeze-drying technology for better performance and advanced modalities.
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- You Can't CAPA What You Can't Classify
- 6 Modeling Approaches That Make Complex Bioprocess Data Useful
- Building Trust In AI For Computerized System Validation
- A Gentler Cell Line Selection Method Using microRNA
- Controls For Retrieval-Augmented Generation In GxP
GUEST COLUMNISTS
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
-
6 Modeling Approaches That Make Complex Bioprocess Data Useful
AI algorithms can reduce data dimensionality more faithfully by interpreting multivariate features relevant to prediction or control.
-
Building Trust In AI For Computerized System Validation
Using AI for CSV might feel like the students are grading their own papers. One consultant explains why it's not the same, namely, there are no subjective judgment calls.
-
A Gentler Cell Line Selection Method Using microRNA
Traditional selection stresses surviving cells. New research shows how structurally interacting RNA may use endogenous microRNA for a faster, nontoxic selection process.
-
Controls For Retrieval-Augmented Generation In GxP
Validation teams deal with inherent variability all the time. The same principles for GMP — think visual inspection — can apply to probabilistic AI systems.
BIOSIMILAR WHITE PAPERS
-
Biopharma Supply, Reimagined: Regional, Resilient Manufacturing
Persistent disruption is redefining biopharma supply chains. Explore how regional manufacturing, integrated risk management, and closer collaboration help build resilience and improve agility.
-
Unlocking The Full Potential Of Antibody-Drug Conjugates (ADCs)6/15/2026
ADCs are evolving rapidly. Gain insight into how success now hinges on managing complexity, delivery, and scalability to turn promising designs into viable therapeutic products.
-
Why Biopharma Breakthroughs Aren't Moving The Market10/20/2025
Biopharma is innovating fast but falling short commercially. Reveal key ecosystem gaps and five strategic actions to help strengthen resilience, accelerate performance, and futureproof organizations.
-
Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators4/28/2025
Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.
-
High-Performing Ionizable Lipids For Controlled Nucleic Acid Delivery9/29/2026
Ionizable lipids are central to effective mRNA delivery, influencing potency, biodistribution, and toxicity. See why advancing delivery beyond the liver will require stronger structure-function insights.
-
ADC Manufacturing: Practices, Challenges, And The Road Ahead6/15/2026
ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.
BIOSIMILAR APP NOTES & CASE STUDIES
- Microbial Recovery And Flow Performance With Membranes
- Discover A System That Can Be Used With Various Cell Culture Media
- Replicate Bioscience And Cytiva Collaborate To Deliver srRNA-LNP Vaccines
- Seed Train Intensification Using High Cell Density Cryopreservation
- Accelerating Technology Transfer Of A Drug Product
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- Formycon And Zydus: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
- Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- And Short-Acting G-CSF Options
- Thyme Companies Launches First New Venture, Thyme Therapeutics, To Build A More Sustainable, Lower-Cost Oncology Biosimilar Model
- LOTTE Biologics And Alvotech Announce US-Based Manufacturing Agreement To Increase Global Supply
- Kamada Announces Expansion Of Biosimilars Portfolio With The Launch Of Two Additional Products In Israel
- Orion Pharma Announces Agreement With Qilu Pharma Europe For Pembrolizumab Biosimilar For European Market
- Formycon Optimizes Biosimilar Development With AI-Powered Technologies: Digital Solutions Enhance Development Efficiency As Part Of The FYB4GROWTH Strategy